Volume 34, Issue 3 pp. 374-376
Brief Report

Low-Dose Cyclosporine A in the Treatment of Severe Atopic Dermatitis Complicated by Chronic Hepatitis C Virus Infection

Maria Gnarra M.D., Ph.D.

Corresponding Author

Maria Gnarra M.D., Ph.D.

Department of Dermatology, Columbia University Medical Center, New York

Address correspondence to Maria Gnarra, M.D., Ph.D., Department of Dermatology, Columbia University Medical Center, 1150 Street Nicholas Avenue, Russ Berrie Pavillion, New York, NY 10032, or e-mail: [email protected].Search for more papers by this author
Clara De Simone M.D., Ph.D.

Clara De Simone M.D., Ph.D.

Institute of Dermatology, Policlinico A. Gemelli, Catholic University, Rome, Italy

Search for more papers by this author
Matteo Garcovich M.D.

Matteo Garcovich M.D.

Division of Gastroenterology, Department of Internal Medicine, Policlinico A. Gemelli, Catholic University, Rome, Italy

Search for more papers by this author
Simone Garcovich M.D., Ph.D.

Simone Garcovich M.D., Ph.D.

Institute of Dermatology, Policlinico A. Gemelli, Catholic University, Rome, Italy

Search for more papers by this author
First published: 06 April 2017
Citations: 3

Abstract

Atopic dermatitis (AD) is the most frequent chronic inflammatory skin disorder in children and is usually accompanied by genetic and environmental factors. Effective management and treatment of AD is challenging and often requires systemic immunosuppressive therapy when refractory to topical treatments. We report a rare association between chronic hepatitis C virus (HCV) and severe AD, management of which required systemic cyclosporine because of its favorable effects on inflammatory and viral-related clinical outcomes.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.